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(73%) during December 2003 to
November 2004, to 23 of 65 (35%)
during December 2004 to July 2005
(p<0.0001). 
Although reports of H5N1 family
clusters slightly increased, the
increase was not statistically signifi-
cant. Nevertheless, we believe any
cluster of cases is of great concern and
should be promptly and thoroughly
investigated because it might be the
first indication of viral mutations
resulting in more efficient person-to-
person spread. Family clustering does
not necessarily indicate person-to-
person transmission, as it may also
result from common household expo-
sures to the same H5N1-infected
poultry or from other exposures, such
as to uncooked poultry products. 
The decrease in proportion of
deaths during 2005 is another epi-
demiologic change that should be
monitored closely because it may
reflect viral adaptation to the human
host. Surveillance for human cases of
avian influenza has been intensified in
recent months, perhaps resulting in
the identification of less severe cases.
Alternatively, more widespread labo-
ratory testing may be associated with
false-positive results. No evidence to
date shows genetic reassortment
between H5N1 and human influenza
A viruses (7). Viruses isolated from
case-patients need to be immediately
sequenced and characterized in rela-
tion to previously circulating viruses
to see whether they are evolving. 
Recent modeling studies suggest
that containing a pandemic at its source
may be possible because emergent
pandemic viruses may be less trans-
missible than commonly assumed (8),
and antiviral treatment and chemopro-
phylaxis may slow the spread (9).
Although the logistics of an attempt to
contain the beginning of a potential
influenza pandemic are formidable, we
believe it is not beyond the capability
of the modern global public health sys-
tem. As WHO (10) has called for,
countries should intensify their pan-
demic preparedness plans and
strengthen international collaborations.
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Imported
Tickborne
Relapsing Fever,
France
To the Editor: Tickborne relaps-
ing fevers caused by Borrelia species
are characterized by >1 recurrent
episodes of fever accompanied by
headache, myalgia, arthralgia, abdom-
inal pain, and eventually by hepatic or
neurologic manifestations. In the Old
World, Borrelia duttonii is endemic in
sub-Saharan East Africa (1) and B.
crocidurae and B. hispanica are dis-
tributed in West Africa and
Mediterranean countries (2). In North
America, B. hermsii, B. turicatae, and
B. parkeri cause mild and sporadic
fever cases, although several out-
breaks have been reported (3).
Relapsing fevers in disease-nonen-
demic countries are infrequently diag-
nosed and probably underdiagnosed
(4). We report 3 patients with relaps-
ing fever diagnosed in France in trav-
elers from disease-endemic countries.
Patient 1, a 29-year-old French
man, was admitted to Hôtel-Dieu in
Paris for a fourth recurrence of a
flulike syndrome. Three weeks earli-
er, he had traveled through Spain and
Morocco, when high-grade fever,
chills, myalgia, and arthralgia sudden-
ly developed. Symptoms quickly
resolved after treatment with salicylate
and acetaminophen, but 3 relapses
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occurred within 20 days. He had a
low-grade fever and persisting myal-
gia. Results of a clinical examination
were normal. Analyses showed elevat-
ed levels of C-reactive protein (CRP)
(368 mg/L), creatine kinase (269
IU/L), and lactate dehydrogenase
(1,149 IU/L). Because of previous
travel in Africa, Giemsa-stained blood
smears were examined for malaria
parasites. They showed helical bacte-
ria suggestive of Borrelia. Polymerase
chain reaction (PCR) of a blood sam-
ple and sequencing of the 16S rRNA
gene identified this bacterium as B.
hispanica. Cefotaxime was adminis-
tered for 72 hours and replaced with
doxycycline, 100 mg twice a day for
10 days. One month later, the patient
was free of symptoms.
Patient 2, a 21-year-old Malian
woman, was admitted to Hôpital de
Mantes in Mantes-la-Jolie and deliv-
ered a normal baby with the gestation-
al age of 36.2 weeks. One month ear-
lier, she experienced a spontaneously
resolving fever with myalgia.
Biologic analyses of the mother
showed anemia (hemoglobin 9.8
g/dL) with an inflammatory syndrome
(CRP 164 mg/L). Giemsa-stained
blood smears showed spirochetes.
Molecular analyses identified these as
B. crocidurae. Results of this analysis
in the newborn were negative. The
patient was treated with doxycycline,
100 mg twice a day for 10 days, and
quickly recovered.
Patient 3, a 21-year-old Mauri-
tanian woman, was admitted to
Avicenne Hospital in Bobigny with a
febrile illness that lasted 4 days. She
had been traveling for 2 months
through Senegal and Mauritania. The
day of her return to France, high-
grade fever (temperature 41°C),
chills, headache, diarrhea, and arthral-
gia developed. Results of a clinical
examination were normal. Laboratory
investigations showed anemia (hemo-
globin 9.8 g/dL) and thrombocytope-
nia (64,000 platelets/µL). Giemsa-
stained blood smears showed spiro-
chetes. Molecular analyses identified
this bacterium as B. crocidurae. The
patient was treated with doxycycline,
100 mg twice a day for 10 days, and
the patient quickly recovered.
Relapsing fevers caused by
Borrelia spp. are rarely reported in
travelers from disease-endemic coun-
tries. Because most infections are
benign, cases are probably neglected.
Since cultivation of the causative
agents can be difficult, diagnosis
relies on microscopic detection of hel-
ical bacteria in stained blood smears.
Blood samples should be obtained
during febrile episodes, but as shown
in patient 2, spirochetes may be visu-
alized on blood smears when the
patient is no longer febrile.
Quantitative buffy-coat analysis that
increases detection sensitivity has
been reported (5). Serologic tests are
being developed to diagnose infection
with B. recurrentis (6).
Detection of Borrelia DNA by
PCR amplification from the blood is
highly sensitive and specific.
Identification can be achieved by
sequencing the 16S rRNA gene (7)
(Figure). Given the high level of
sequence conservation (7), mutations
can be informative. The identifying
nucleotides for B. crocidurae, B. his-
panica, and B. duttoni were at posi-
tions 65, 181, 381, and 596. Therefore,
sequence analysis of the first 600
nucleotides (nt) in the 16S rRNA gene
is sufficient to differentiate B. crocidu-
rae, B. hispanica, and B. duttonii.
The complete Borrelia sequence
obtained from the patient 1 showed
99.93% identity with B. hispanica (1
nt difference), 99.79% with B. cro-
cidurae (3 nt differences), and
99.72% identity with B. duttonii (4 nt
differences). This patient was infected
with  B. hispanica during his travel
through Spain or Morocco, which is
consistent with the distribution of this
species. Comparison of 1,430 nt from
sequences from patients 2 and 3
showed 99.93% identity with the
sequence of B. crocidurae (1 nt differ-
ence). B. crocidurae occurs mostly in
sub-Saharan countries of West Africa
(Senegal, Mali, and Mauritania),
where patients 2 and 3 were likely to
have been infected. 
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Figure. Unweighted pair group with mathematical average rooted tree of complete
sequences of the Borrelia 16S rRNA gene. Sequences from databanks are indicated by
their accession numbers.LETTERS
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Physicians should be alert for
relapsing fever in travelers, and this
diagnosis should be considered in
febrile patients from disease-endemic
regions. Diagnosis relies upon exami-
nation of stained blood smears. Where
available, molecular methods are
highly efficient to detect and identify
bacterial species. Other tickborne
infections (e.g., those with Rickettsia
spp.) should also be considered in
patients returning from disease-
endemic countries (8). The recom-
mended treatment is doxycycline,
although it can cause a Jarish-
Herxheimer reaction in some patients.
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Neonatal Moraxella
osloensis
Ophthalmia
To the Editor: Moraxella osloen-
sis is an aerobic, gram-negative, lac-
tose-nonfermenting coccobacillus. It
is a commensal of the human upper
respiratory tract and occasionally of
the skin and urogenital tract (1).
Unlike M. catarrhalis, M. osloensis is
rarely pathogenic in humans.
However, several cases of serious
infections caused by this organism
have been documented (2–6). While
cases of nongonococcal, nonchlamy-
dial, neonatal ophthalmia have been
reported in which the causative agent
was  M. catarrhalis (7,8), to our
knowledge, this case is the first report
of neonatal ophthalmia due to M.
osloensis.
A 3-week-old, previously healthy
boy was seen at the emergency depart-
ment with a 48-hour history of yellow
drainage from and swelling in both
eyes. One day before admission, the
drainage increased; the child could not
open his eyes spontaneously. He had
been eating well and was normally
active. Aside from mild fussiness, no
other symptoms were noted.
The child was born full-term with-
out complications to a gravida 6, para
5–6 mother. He received normal new-
born care, including topical erythro-
mycin ointment to the eyes. Aside
from some mild jaundice at 6 days of
age, he had been healthy. The mother
denied any history of sexually trans-
mitted disease.
On examination, the infant’s tem-
perature was 38°C rectally, heart rate
144 beats/min, respirations 26/min,
and blood pressure 94/60 mm Hg. The
child appeared well developed and
was fussy but showed no symptoms
of toxicity. Both eyelids were marked-
ly swollen and erythematous, and a
yellow, purulent discharge was noted
bilaterally. The sclera and conjuncti-
vae were injected bilaterally. An oph-
thalmologist recorded that the red
reflex was intact bilaterally and the
corneas were clear. Intravenous cefo-
taxime, oral erythromycin, and topical
erythromycin ointment to the eyes
were recommended. The leukocyte
count was 11,400 cells/mm3 with a
normal differential. Hemoglobin
level, hematocrit, platelet count, and
bilirubin level were all within normal
range. Urinalysis results as well as
urine, blood, and cerebrospinal fluid
cultures were negative. Secretions
from the eyes were collected and sent
for Gram stain and bacterial culture as
well as chlamydial culture. Gram
stain showed few gram-variable
cocci.
The child’s eyes were flushed with
copious amounts of normal saline,
and a dose of intravenous cefotaxime
and ampicillin was administered in
the emergency department. He was
admitted to the hospital for presumed
ophthalmia neonatorum. The follow-
ing day, decreased lid swelling, ery-
thema, and eye discharge were
observed, with trace conjunctival
injection and minimal chemosis. 
The child’s condition improved
markedly during the next 24–48
hours. Cultures of the secretions
obtained from the eye grew presumed
Neisseria species as a pure culture.
The isolate was sent to the Allegheny